AUSTRALIA
Spruson & Ferguson celebrates success at regional intellectual property awards
We are pleased to announce that Spruson & Ferguson has been recognised with multiple prestigious accolades at leading intellectual property award ceremonies. "It was a fantastic night at the Asia...
We are pleased to announce that Spruson & Ferguson has been recognised with multiple prestigious accolades at leading intellectual...
Read More
AUSTRALASIA
Australia | $5.8 million privacy penalty – a first for Privacy Law enforcement
A wake-up call for organisations required to comply with privacy laws, the Australian Federal Court’s $5.8 million penalty against Australian Clinical Labs Limited (ACL) marks the first civil penalty...
A wake-up call for organisations required to comply with privacy laws, the Australian Federal Court’s $5.8 million penalty against...
Read More
AUSTRALIA
Australia | Responsible AI use & lessons from Deloitte’s “Dodgy Report”
A Deloitte report for the Australian Department of Employment and Workplace Relations, compiled with the assistance of AI, was found to contain reference errors and a fabricated quote from...
A Deloitte report for the Australian Department of Employment and Workplace Relations, compiled with the assistance of AI, was...
Read More
AUSTRALIA
The 2025 Pharmaceutical Patent Review
Welcome to Spruson & Ferguson’s review of the most notable developments in Australian pharmaceutical patent law in the past year. The year has seen a series of landmark decisions from...
Welcome to Spruson & Ferguson’s review of the most notable developments in Australian pharmaceutical patent law in the past...
Read More
AUSTRALIA
Australia and New Zealand | Guide to differences in patent prosecution
A side-by-side look at patent prosecution in Australia and New Zealand While both jurisdictions share common roots, namely the Statute of Monopolies 1623, the Australia and New Zealand patent systems...
A side-by-side look at patent prosecution in Australia and New Zealand While both jurisdictions share common roots, namely the Statute...
Read More
AUSTRALIA
Australia | Part 2: Regulatory considerations for orphan drugs
Following our first article on orphan drug development, which examined key patenting options and strategies, our second article sets out the key regulatory considerations in Australia. Orphan drug patent strategy...
Following our first article on orphan drug development, which examined key patenting options and strategies, our second article sets...
Read More
AUSTRALIA
Australia | Part 1: Patenting orphan drugs
Collectively, rare diseases impact approximately 8% of the Australian population, or around 2 million people. Orphan drugs are pharmaceutical products developed to treat rare diseases, however with each drug...
Collectively, rare diseases impact approximately 8% of the Australian population, or around 2 million people. Orphan drugs are pharmaceutical...
Read More

Find Your Expert

Experts

Contact Us

Enquiries

Receive Insights

Subscribe